| Name | Title | Contact Details |
|---|---|---|
Kevin Montgomery |
Co-Founder and Chief Innovation Officer | Profile |
Raj Bhavsar |
Chief Technology Officer | Profile |
Brave Health is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
South Carolina Hospital Association is a West Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BlueCross BlueShield of Louisiana is a Baton Rouge, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EarlySense is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. EarlySense is based in Waltham, MA. You can find more information on EarlySense at www.earlysense.com
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.